Đang chuẩn bị liên kết để tải về tài liệu:
Ipilimumab and immune-mediated adverse events: A case report of anti-CTLA4 induced ileitis

Không đóng trình duyệt đến khi xuất hiện nút TẢI XUỐNG

Ipilimumab is a fully human monoclonal antibody directed against cytotoxic T-lymphocyte antigen-4 , a key negative regulator of T-cell activation approved by the Food and Drug Administration as of March 2011 for the treatment of metastatic melanoma. |

TÀI LIỆU LIÊN QUAN

Nivolumab plus ipilimumab versus nivolumab in individuals with treatmentnaive programmed death-ligand 1 positive metastatic soft tissue sarcomas: A multicentre retrospective study

Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: The IMAGE study

Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: A population-based cohort study in Ontario, Canada

A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: The IpiGlio trial protocol

Intracranial antitumor responses of nivolumab and ipilimumab: A pharmacodynamic and pharmacokinetic perspective, a scoping systematic review

PRISM protocol: A randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in firstline treatment of patients with advanced or metastatic renal cell carcinoma

Unmasking of intracranial metastatic melanoma during ipilimumab/nivolumab therapy: Case report and literature review

A multicenter open-label phase II trial to evaluate nivolumab and ipilimumab for 2nd line therapy in elderly patients with advanced esophageal squamous cell cancer (RAMONA)

PRIME-HCC: Phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma

Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2 - positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217)
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.